Medical Devices industry M&A deals total $1.4bn globally in April 2022

Total Medical devices industry M&A deals worth $1.4bn were announced globally in April 2022, led by Wallaby Medical’s $541.63m acquisition of Phenox, according to GlobalData’s deals database.

The value marked an increase of 266.2% over the previous month of $390.55m and a drop of 81.4% when compared with the last 12-month average, which stood at $7.68bn.

Comparing M&A deals value in different regions of the globe, Europe held the top position, with total announced deals in the period worth $883.29m. At the country level, the Germany topped the list in terms of deal value at $541.63m.

In terms of volumes, North America emerged as the top region for Medical devices industry M&A deals globally, followed by Europe and then Asia-Pacific.

The top country in terms of M&A deals activity in April 2022 was the US with 16 deals, followed by the Germany with four and China with two.

In 2022, as of April, Medical devices M&A deals worth $8.59bn were announced globally, marking an increase of 72.6% year on year.

Medical devices industry M&A deals in April 2022: Top deals

The top five M&A deals accounted for 77.9% of the overall value during April 2022.

The combined value of the top five Medical devices M&A deals stood at $1.12bn, against the overall value of $1.4bn recorded for the month.

The top five Medical devices industry M&A deals of April 2022 tracked by GlobalData were:

1) Wallaby Medical $541.63m acquisition deal with Phenox

2) The $170m acquisition of Inform Diagnostics by Fulgent Genetics

3) Integer $141.73m acquisition deal with Aran Biomedical

4) The $140m acquisition of AltheaDx by Castle Biosciences

5) Cochlear $122.03m acquisition deal with Oticon Medical